@article{Hoang_K-2022_95020,
title = {Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments},
author = {Hoang, K. and Watt, H. and Golemme, M. and Perry, R. and Ritchie, C. and Wilson, D. and Pickett, J. and Fox, C. and Howard, R. and Malhotra, P.},
month = {aug},
year = {2022},
abstract = {BACKGROUND: Guanfacine is a α2A adrenergic receptor agonist approved for treating attention deficit hyperactivity disorder (ADHD). It is thought to act via postsynaptic receptors in the prefrontal cortex, modulating executive functions including the regulation of attention. Attention is affected early in Alzheimer's disease (AD), and this may relate to pathological changes within the locus coeruleus, the main source of noradrenergic pathways within the brain. Given that cholinergic pathways, also involved in attention, are disrupted in AD, the combination of noradrenergic and cholinergic treatments may have a synergistic effect on symptomatic AD. The primary objective of the NorAD trial is to evaluate the change in cognition with 12 weeks of treatment of extended-release guanfacine (GXR) against a placebo as a combination therapy with cholinesterase inhibitors in participants with mild to moderate Alzheimer's disease.},
volume = {23},
issue = {1},
journal = {Trials},
publisher = {Springer Nature},
url = {https://doi.org/10.1186/s13063-022-06190-3},
}
